Valuation : Celltrion, Inc.

Market Cap 45,912B 33.23B 28.52B 26.71B 24.45B 46.07B 3,174B 46.2B 316B 124B 1,600B 125B 122B 5,294B P/E 2026 *
29.1x
P/E 2027 * 25.2x
Enterprise Value 48.11B 34.82M 29.89M 27.98M 25.62M 48.27M 3.33B 48.41M 331M 130M 1.68B 131M 128M 5.55B EV / Sales 2026 *
8.78x
EV / Sales 2027 * 7.52x
Free-Float
60.59%
Yield 2026 *
0.4%
Yield 2027 * 0.43%
Manager TitleAgeSince
Chief Executive Officer 65 20/03/2015
Chief Executive Officer 42 26/03/2021
President 50 13/02/2026
Director TitleAgeSince
Chairman 68 -
Director/Board Member 61 01/04/2005
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.10%+0.44%+2.80%+24.32% 50.96B
+2.65%+4.45%+481.36%+567.32% 46.18B
+0.33%+2.47%+38.97%+19.80% 43.04B
-0.88%+0.90%+24.11%+87.74% 42.73B
-2.27%-3.02%+14.22%+51.50% 33.48B
-1.21%-0.17%+29.16%+135.38% 17.28B
-0.36%-2.14% - - 16.43B
+0.25%+0.25%+12.03%+30.68% 14.73B
+0.44%+1.70%+82.07%+47.92% 14.09B
Average -0.11%+0.34%+85.59%+120.58% 30.99B
Weighted average by Cap. +0.04%+0.57%+104.35%+141.83%

Financials

2026 *2027 *
Net sales 5,480B 3.97B 3.4B 3.19B 2.92B 5.5B 379B 5.51B 37.75B 14.76B 191B 14.89B 14.57B 632B 6,294B 4.56B 3.91B 3.66B 3.35B 6.31B 435B 6.33B 43.35B 16.95B 219B 17.1B 16.73B 726B
Net income 1,511B 1.09B 939M 879M 805M 1.52B 104B 1.52B 10.41B 4.07B 52.64B 4.11B 4.02B 174B 1,763B 1.28B 1.1B 1.03B 939M 1.77B 122B 1.77B 12.15B 4.75B 61.43B 4.79B 4.69B 203B
Net Debt 2,199B 1.59B 1.37B 1.28B 1.17B 2.21B 152B 2.21B 15.14B 5.92B 76.6B 5.97B 5.85B 254B 1,409B 1.02B 875M 820M 750M 1.41B 97.4B 1.42B 9.71B 3.79B 49.09B 3.83B 3.75B 162B
Logo Celltrion, Inc.
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A